دورية أكاديمية
أعرض في EDS

Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.

التفاصيل البيبلوغرافية
العنوان: Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
المؤلفون: Lazăr DC; Department of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania. lazar.daniela@umft.ro., Avram MF; Department of Surgery X, 1 Surgery Clinic, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania., Romoșan I; Department of Internal Medicine I, University Medical Clinic, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania., Cornianu M; Department of Pathology, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania., Tăban S; Department of Pathology, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania., Goldiș A; Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy 'Victor Babeş', Timişoara 300041, Timiş County, Romania.
المصدر: World journal of gastroenterology [World J Gastroenterol] 2018 Aug 28; Vol. 24 (32), pp. 3583-3616.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-
مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*therapeutic use , Costimulatory and Inhibitory T-Cell Receptors/*antagonists & inhibitors , Immunotherapy/*methods , Stomach Neoplasms/*drug therapy , Tumor Microenvironment/*immunology, Antineoplastic Agents, Immunological/pharmacology ; Biological Products/pharmacology ; Biological Products/therapeutic use ; Biomarkers, Tumor/immunology ; Biomarkers, Tumor/metabolism ; Costimulatory and Inhibitory T-Cell Receptors/immunology ; Costimulatory and Inhibitory T-Cell Receptors/metabolism ; Humans ; Immunotherapy/trends ; Molecular Targeted Therapy/methods ; Molecular Targeted Therapy/trends ; Prognosis ; Signal Transduction/drug effects ; Signal Transduction/immunology ; Stomach Neoplasms/immunology ; Stomach Neoplasms/mortality ; Treatment Outcome ; Tumor Microenvironment/drug effects
مستخلص: Despite a decrease in gastric cancer incidence, the development of novel biologic agents and combined therapeutic strategies, the prognosis of gastric cancer remains poor. Recently, the introduction of modern immunotherapy, especially using immune checkpoint inhibitors, led to an improved prognosis in many cancers. The use of immunotherapy was also associated with manageable adverse event profiles and promising results in the treatment of patients with gastric cancer, especially in heavily pretreated patients. These data have led to an accelerated approval of some checkpoint inhibitors in this setting. Understanding the complex relationship between the host immune microenvironment and tumor and the immune escape phenomenon leading to cancer occurrence and progression will subsequently lead to the identification of prognostic immune markers. Furthermore, this understanding will result in the discovery of both new mechanisms for blocking tumor immunosuppressive signals and pathways to stimulate the local immune response by targeting and modulating different subsets of immune cells. Due to the molecular heterogeneity of gastric cancers associated with different clinico-biologic parameters, immune markers expression and prognosis, novel immunotherapy algorithms should be personalized and addressed to selected subsets of gastric tumors, which have been proven to elicit the best clinical responses. Future perspectives in the treatment of gastric cancer include tailored dual immunotherapies or a combination of immunotherapy with other targeted agents with synergistic antitumor effects.
Competing Interests: Conflict-of-interest statement: The authors have no conflict of interest to report.
References: Lancet. 2010 Aug 28;376(9742):687-97. (PMID: 20728210)
Clin Cancer Res. 2010 Mar 1;16(5):1662-72. (PMID: 20179239)
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20852-7. (PMID: 19088198)
Expert Opin Investig Drugs. 2014 Jul;23(7):925-42. (PMID: 24806575)
Chin J Cancer. 2010 Apr;29(4):359-64. (PMID: 20346208)
Science. 2011 Mar 25;331(6024):1565-70. (PMID: 21436444)
Arch Pharm Res. 2010 Nov;33(11):1789-95. (PMID: 21116782)
Intern Emerg Med. 2014 Apr;9(3):303-9. (PMID: 23054412)
Oncotarget. 2016 Feb 16;7(7):7940-51. (PMID: 26799288)
Medicine (Baltimore). 2015 Oct;94(43):e1911. (PMID: 26512615)
Science. 2002 Oct 25;298(5594):850-4. (PMID: 12242449)
Nat Rev Cancer. 2012 Mar 22;12(4):237-51. (PMID: 22437869)
J Exp Med. 2005 Oct 17;202(8):1075-85. (PMID: 16230475)
Lancet Oncol. 2016 Jun;17(6):717-726. (PMID: 27157491)
World J Gastroenterol. 2014 Nov 28;20(44):16433-42. (PMID: 25469011)
Oncotarget. 2017 May 22;8(34):57386-57398. (PMID: 28915679)
Cancer Immunol Immunother. 2013 Mar;62(3):553-61. (PMID: 23090288)
Cancer Cell Int. 2017 Dec 02;17:114. (PMID: 29213216)
Mol Clin Oncol. 2017 Dec;7(6):1073-1078. (PMID: 29285377)
Nat Med. 2004 May;10(5):475-80. (PMID: 15122249)
J Hematol Oncol. 2017 Jan 25;10(1):34. (PMID: 28122590)
Int J Oncol. 2014 Mar;44(3):662-8. (PMID: 24398900)
J Immunother. 2008 Feb-Mar;31(2):180-8. (PMID: 18481387)
Int J Cancer. 1998 Oct 5;78(2):202-8. (PMID: 9754653)
Nat Med. 2015 May;21(5):449-56. (PMID: 25894828)
Chin Clin Oncol. 2017 Oct;6(5):53. (PMID: 29129093)
Br Med J. 1957 Apr 6;1(5022):779-86. (PMID: 13404306)
N Engl J Med. 2012 Jun 28;366(26):2455-65. (PMID: 22658128)
Sci Rep. 2016 Nov 28;6:37933. (PMID: 27892511)
Ann Oncol. 2013 Oct;24 Suppl 6:vi57-63. (PMID: 24078663)
Cancer Res. 2015 Jun 1;75(11):2139-45. (PMID: 25977340)
Oncotarget. 2017 May 30;8(56):95083-95094. (PMID: 29221113)
Oncol Rep. 2012 Nov;28(5):1743-9. (PMID: 22948809)
PLoS One. 2013 Sep 05;8(9):e74430. (PMID: 24040244)
J Surg Res. 2001 Sep;100(1):32-8. (PMID: 11516202)
Br J Cancer. 2008 Nov 18;99(10):1704-11. (PMID: 18941457)
N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992)
Am J Surg Pathol. 2016 Nov;40(11):1496-1506. (PMID: 27465786)
Mol Oncol. 2016 Dec;10(10):1551-1558. (PMID: 27720576)
Nat Rev Immunol. 2013 Apr;13(4):227-42. (PMID: 23470321)
Virchows Arch. 2006 Mar;448(3):344-53. (PMID: 16261379)
Nat Commun. 2014 Oct 28;5:5241. (PMID: 25348003)
Cancer Med. 2014 Apr;3(2):362-75. (PMID: 24515916)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Zhonghua Zhong Liu Za Zhi. 2010 Jun;32(6):410-4. (PMID: 20819479)
J Gastroenterol Hepatol. 2014;29(7):1435-41. (PMID: 25587614)
Br J Cancer. 2005 May 9;92(9):1746-53. (PMID: 15856045)
World J Gastrointest Oncol. 2017 Jul 15;9(7):293-299. (PMID: 28808502)
J Immunother Cancer. 2015 Apr 21;3:11. (PMID: 25901283)
Cancer Res. 2010 Nov 15;70(22):9031-40. (PMID: 21045153)
J Immunother. 2011 Jan;34(1):1-15. (PMID: 21150709)
Cancer Biother Radiopharm. 2013 May;28(4):303-9. (PMID: 23506427)
Nihon Gan Chiryo Gakkai Shi. 1990 May 20;25(5):978-89. (PMID: 2391445)
Oncotarget. 2015 Dec 8;6(39):41600-19. (PMID: 26486085)
Oncotarget. 2016 Apr 26;7(17):24269-83. (PMID: 27009855)
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. (PMID: 24714771)
J Immunol Res. 2014;2014:897214. (PMID: 24741629)
Lancet. 2014 Jan 4;383(9911):31-39. (PMID: 24094768)
Acta Pathol Microbiol Scand. 1965;64:31-49. (PMID: 14320675)
Oncoimmunology. 2015 Jun 3;5(2):e1054598. (PMID: 27057426)
N Engl J Med. 2012 Jun 28;366(26):2443-54. (PMID: 22658127)
Int Immunopharmacol. 2013 Jun;16(2):332-40. (PMID: 23639256)
Oncol Rep. 2012 Aug;28(2):453-8. (PMID: 22614133)
J Clin Invest. 2005 Dec;115(12):3623-33. (PMID: 16308572)
Oncoimmunology. 2015 Nov 09;5(5):e1100789. (PMID: 27467911)
Cytotherapy. 2015 Jul;17(7):979-88. (PMID: 25890480)
Gastroenterology. 2008 Apr;134(4):988-97. (PMID: 18395080)
Chin J Cancer. 2017 Jul 29;36(1):61. (PMID: 28754154)
Cancer Immunol Res. 2015 May;3(5):436-43. (PMID: 25941355)
Br J Cancer. 2011 Jun 28;105(1):38-43. (PMID: 21654677)
N Engl J Med. 2016 Nov 03;375(18):1749-1755. (PMID: 27806233)
J Exp Med. 2000 Oct 2;192(7):1027-34. (PMID: 11015443)
Eur J Cancer. 2008 Sep;44(13):1875-82. (PMID: 18617393)
Gastroenterology. 2015 Jan;148(1):137-147.e9. (PMID: 25254613)
Cancer Med. 2018 Jan;7(1):123-133. (PMID: 29239137)
J Immunother. 2003 Jul-Aug;26(4):332-42. (PMID: 12843795)
Gastric Cancer. 2013 Oct;16(4):473-9. (PMID: 23179366)
Onco Targets Ther. 2016 May 04;9:2649-54. (PMID: 27226727)
Fam Cancer. 2009;8(3):215-20. (PMID: 19152022)
N Engl J Med. 2016 Nov 10;375(19):1823-1833. (PMID: 27718847)
Gastroenterology. 2015 Oct;149(5):1153-1162.e3. (PMID: 26073375)
Gut. 2017 May;66(5):794-801. (PMID: 26801886)
Br J Cancer. 2008 Jan 15;98(1):148-53. (PMID: 18087278)
J Cancer. 2017 Jul 2;8(10):1826-1832. (PMID: 28819380)
World J Gastroenterol. 2016 Jan 21;22(3):1190-201. (PMID: 26811657)
Chin J Cancer. 2016 May 27;35:49. (PMID: 27233623)
J Surg Oncol. 2013 Apr;107(5):517-22. (PMID: 23129549)
Cancer Res. 2015 Aug 1;75(15):3020-31. (PMID: 26116496)
Cancer Res. 1997 Oct 15;57(20):4465-8. (PMID: 9377553)
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2731-6. (PMID: 10694580)
Cancer. 1997 Jun 15;79(12):2320-8. (PMID: 9191519)
Clin Cancer Res. 2015 Dec 15;21(24):5427-33. (PMID: 26519060)
Acta Histochem. 2006;108(1):19-24. (PMID: 16530813)
J Exp Med. 2011 Mar 14;208(3):577-92. (PMID: 21383057)
Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317)
Gastric Cancer. 2016 Jan;19(1):42-52. (PMID: 25424150)
J Exp Clin Cancer Res. 2010 Aug 30;29:118. (PMID: 20799994)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
Anticancer Res. 2006 May-Jun;26(3B):2237-42. (PMID: 16821594)
Int J Clin Exp Med. 2015 May 15;8(5):7728-36. (PMID: 26221323)
N Engl J Med. 2008 Jun 19;358(25):2704-15. (PMID: 18565863)
Nature. 1992 Nov 19;360(6401):264-5. (PMID: 1436108)
Gastroenterology. 2013 Sep;145(3):554-65. (PMID: 23684942)
Cancer. 2000 Feb 1;88(3):577-83. (PMID: 10649250)
Oncogene. 2008 Mar 6;27(11):1562-71. (PMID: 17873905)
Gastroenterology. 2011 Oct;141(4):1422-31, 1431.e1-6. (PMID: 21763239)
Gastric Cancer. 2004;7(4):240-5. (PMID: 15616772)
Bratisl Lek Listy. 2001;102(1):5-14. (PMID: 11723675)
Gastroenterol Hepatol Bed Bench. 2013 Fall;6(4):178-82. (PMID: 24834269)
Medicine (Baltimore). 2015 Sep;94(39):e1631. (PMID: 26426650)
PLoS One. 2013 Dec 23;8(12):e83710. (PMID: 24376736)
Cancer Biother Radiopharm. 2005 Apr;20(2):173-80. (PMID: 15869451)
World J Gastroenterol. 2010 Dec 28;16(48):6155-62. (PMID: 21182234)
Vaccine. 2001 Mar 21;19(17-19):2576-82. (PMID: 11257395)
World J Gastrointest Oncol. 2017 May 15;9(5):194-208. (PMID: 28567184)
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6. (PMID: 19318937)
PLoS One. 2017 Aug 10;12(8):e0182692. (PMID: 28796808)
J Immunother. 2003 Sep-Oct;26(5):403-11. (PMID: 12973029)
PLoS One. 2013 May 20;8(5):e63712. (PMID: 23700430)
Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. (PMID: 12427970)
Oncol Rep. 2013 May;29(5):1756-62. (PMID: 23440298)
J Cancer. 2017 Jun 3;8(9):1579-1585. (PMID: 28775777)
Int J Clin Exp Med. 2015 May 15;8(5):8086-93. (PMID: 26221374)
Int J Clin Exp Med. 2014 Oct 15;7(10):3181-92. (PMID: 25419348)
World J Gastroenterol. 2015 May 21;21(19):5778-93. (PMID: 26019442)
J Immunol. 1999 Jan 1;162(1):577-84. (PMID: 9886435)
J Clin Invest. 2007 May;117(5):1195-203. (PMID: 17476349)
Gastroenterology. 2005 May;128(6):1567-78. (PMID: 15887152)
Int J Cancer. 2014 Sep 15;135(6):1390-8. (PMID: 24615495)
Cancer Biomark. 2013;13(1):11-20. (PMID: 23736017)
Cancer Res. 2005 Nov 1;65(21):9751-61. (PMID: 16266996)
J Clin Gastroenterol. 2002 Apr;34(4):416-20. (PMID: 11907352)
World J Gastroenterol. 2015 Mar 7;21(9):2777-85. (PMID: 25759549)
Ann Surg Oncol. 2011 Sep;18(9):2585-93. (PMID: 21347781)
Expert Rev Clin Pharmacol. 2017 Jun;10(6):609-619. (PMID: 28349740)
Arch Surg. 1990 Feb;125(2):200-5. (PMID: 1689143)
Cancer. 2006 May 1;106(9):1908-16. (PMID: 16568451)
Gut. 2015 Nov;64(11):1721-31. (PMID: 25385008)
Clin Cancer Res. 2002 Jun;8(6):1767-71. (PMID: 12060615)
Tissue Antigens. 2007 Jan;69(1):19-27. (PMID: 17212704)
Hum Pathol. 2014 Feb;45(2):285-93. (PMID: 24331841)
Gastrointest Cancer. 2017;7:1-11. (PMID: 28757801)
Oncology (Williston Park). 2009 May;23(6):488-96. (PMID: 19544689)
J Exp Clin Cancer Res. 2010 Oct 11;29:134. (PMID: 20937115)
BMC Gastroenterol. 2009 Sep 04;9:65. (PMID: 19732435)
Iowa Orthop J. 2006;26:154-8. (PMID: 16789469)
PLoS One. 2015 Dec 29;10(12):e0144192. (PMID: 26714314)
Gastroenterology. 1995 Nov;109(5):1685-99. (PMID: 7557155)
Biomed Res Int. 2017;2017:4346576. (PMID: 28758114)
Arq Bras Cir Dig. 2012 Apr-Jun;25(2):114-7. (PMID: 23381755)
Oncotarget. 2016 May 31;7(22):32925-32. (PMID: 27147580)
Front Oncol. 2014 Apr 02;4:70. (PMID: 24765614)
N Engl J Med. 1987 Apr 9;316(15):889-97. (PMID: 3493432)
Oncotarget. 2015 Aug 21;6(24):20592-603. (PMID: 26008981)
BMC Med Genomics. 2017 Dec 06;10(1):74. (PMID: 29212506)
Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959)
J Immunol. 2013 Jan 15;190(2):794-804. (PMID: 23248262)
Am Soc Clin Oncol Educ Book. 2017;37:292-300. (PMID: 28561677)
J Natl Cancer Inst. 1994 Aug 3;86(15):1159-66. (PMID: 8028037)
Cancer Immunol Immunother. 2005 Apr;54(4):307-14. (PMID: 15599732)
Mol Clin Oncol. 2015 May;3(3):699-705. (PMID: 26137290)
Int J Cancer. 1997 Jun 11;71(6):978-81. (PMID: 9185700)
Lancet Oncol. 2014 Oct;15(11):1224-35. (PMID: 25240821)
Oncoimmunology. 2017 Feb 21;6(4):e1293215. (PMID: 28507801)
J Natl Cancer Inst. 2014 Nov 24;107(1):364. (PMID: 25424197)
Nat Med. 2003 Jun;9(6):669-76. (PMID: 12778165)
J Cancer Res Clin Oncol. 2010 Oct;136(10):1585-95. (PMID: 20221835)
Lancet Oncol. 2016 Nov;17(11):1497-1508. (PMID: 27745820)
Clin Cancer Res. 2011 Jul 1;17(13):4550-7. (PMID: 21498393)
Anticancer Drugs. 2013 Nov;24(10):999-1006. (PMID: 23949254)
Immunol Lett. 2010 Nov 30;134(1):47-54. (PMID: 20727912)
Mod Pathol. 2003 Jul;16(7):641-51. (PMID: 12861059)
J Hematol Oncol. 2017 Apr 24;10(1):86. (PMID: 28434400)
Gastric Cancer. 2022 Jan;25(1):197-206. (PMID: 34468869)
J Clin Invest. 2003 Jul;112(1):109-17. (PMID: 12840065)
Ann Oncol. 2016 Mar;27(3):494-501. (PMID: 26673353)
Cancer Immunol Immunother. 1999 Jul;48(4):189-94. (PMID: 10431688)
Hum Cell. 2006 Feb;19(1):24-9. (PMID: 16643604)
Semin Oncol. 2015 Aug;42(4):663-71. (PMID: 26320069)
N Engl J Med. 2011 Jun 30;364(26):2517-26. (PMID: 21639810)
J Immunol. 1990 Sep 1;145(5):1615-20. (PMID: 1974569)
Anticancer Res. 2010 Apr;30(4):1093-103. (PMID: 20530414)
J Exp Med. 2013 Aug 26;210(9):1695-710. (PMID: 23897981)
Immunity. 2013 Jul 25;39(1):1-10. (PMID: 23890059)
Oncoimmunology. 2015 Aug 31;5(3):e1086862. (PMID: 27141343)
Biochem Cell Biol. 2012 Dec;90(6):701-8. (PMID: 22992138)
Oncol Rep. 2011 Feb;25(2):469-76. (PMID: 21165574)
J Surg Oncol. 2010 Dec 1;102(7):742-7. (PMID: 20872813)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Nat Med. 2007 Jan;13(1):84-8. (PMID: 17159987)
Ann Pharmacother. 2011 Apr;45(4):510-9. (PMID: 21505108)
Gastroenterology. 2013 Jan;144(1):155-66. (PMID: 23041326)
Cancer Res. 2014 Apr 1;74(7):1933-44. (PMID: 24691994)
J Gastrointestin Liver Dis. 2014 Sep;23(3):249-53. (PMID: 25267951)
J Immunol. 2001 Jan 1;166(1):678-89. (PMID: 11123353)
Stem Cells Dev. 2013 Nov 1;22(21):2836-48. (PMID: 23777268)
J Exp Med. 1996 Jan 1;183(1):283-7. (PMID: 8551233)
Gastroenterology. 2009 Sep;137(3):824-33. (PMID: 19445939)
J Immunother. 2009 Jun;32(5):498-507. (PMID: 19609242)
Oncogene. 2008 Sep 18;27(41):5464-76. (PMID: 18794881)
PLoS One. 2015 Jun 26;10(6):e0131403. (PMID: 26114883)
J Clin Immunol. 2012 Dec;32(6):1332-9. (PMID: 22760549)
Oncotarget. 2016 Dec 6;7(49):80426-80434. (PMID: 27741514)
Anticancer Res. 1992 May-Jun;12(3):645-8. (PMID: 1622120)
Cancer Sci. 2018 Jan;109(1):43-53. (PMID: 29034543)
Blood. 2002 Mar 15;99(6):2114-21. (PMID: 11877287)
Cell. 2010 Mar 19;140(6):883-99. (PMID: 20303878)
Biologics. 2012;6:73-82. (PMID: 22532775)
JAMA Oncol. 2018 May 10;4(5):e180013. (PMID: 29543932)
J Immunol. 2010 Aug 15;185(4):2580-8. (PMID: 20644173)
Int J Oncol. 2012 Oct;41(4):1297-304. (PMID: 22842485)
J Exp Med. 1996 Jun 1;183(6):2593-603. (PMID: 8676080)
Clin Exp Immunol. 2011 Aug;165(2):180-9. (PMID: 21592111)
Ann Surg. 2018 Mar;267(3):504-513. (PMID: 28002059)
J Immunother Cancer. 2017 Feb 21;5:16. (PMID: 28239469)
Oncotarget. 2017 May 16;8(40):67094-67103. (PMID: 28978018)
Gastric Cancer. 2017 May;20(3):407-415. (PMID: 27629881)
Curr Opin Immunol. 2012 Apr;24(2):207-12. (PMID: 22236695)
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. (PMID: 25964334)
Int J Clin Exp Pathol. 2014 Jul 15;7(8):4685-94. (PMID: 25197340)
Cancer Immunol Immunother. 2012 Dec;61(12):2251-9. (PMID: 22674056)
Ann Oncol. 2009 Sep;20(9):1529-1534. (PMID: 19474114)
Lancet. 2017 Dec 2;390(10111):2461-2471. (PMID: 28993052)
World J Gastroenterol. 2014 Feb 21;20(7):1657-66. (PMID: 24587645)
Cancer Lett. 2000 Oct 16;159(1):103-8. (PMID: 10974412)
فهرسة مساهمة: Keywords: Gastric cancer; Immune checkpoint inhibitors; Immunotherapy; Prognostic significance; Tumor immune microenvironment
المشرفين على المادة: 0 (Antineoplastic Agents, Immunological)
0 (Biological Products)
0 (Biomarkers, Tumor)
0 (Costimulatory and Inhibitory T-Cell Receptors)
تواريخ الأحداث: Date Created: 20180901 Date Completed: 20181211 Latest Revision: 20230928
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6113718
DOI: 10.3748/wjg.v24.i32.3583
PMID: 30166856
قاعدة البيانات: MEDLINE
الوصف
تدمد:2219-2840
DOI:10.3748/wjg.v24.i32.3583